Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Principal Investigator
Name
Jing Zhou
Degrees
Ph.D.
Institution
Department of Family and Preventive Medicine
Position Title
student and research assistant
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-591
Initial CDAS Request Approval
Feb 27, 2020
Title
Treatment effect on the Survival Time of Lung Cancer Patients
Summary
Lung cancer is the leading cause of cancer death for both men and women in the United States. According to data of 2009-2013 from the NCI’s Surveillance, Epidemiology, and End Results (SEER) Program, more people are dying from lung cancer each year in the US than colon, breast, and prostate cancer combined1. This striking fact about lung cancer is due to its high prevalence, low survival rate and poor prognosis.

The traditional treatments for lung cancer are surgery, radiation therapy, chemotherapy. When doctors make therapeutic plans, several factors will be considered, including tumor size, stage, the major type of the lung cancer, ect3. Thus, survival analysis comparing the survival time, hazardous rate of lung cancer patients among different treatment groups will provide valuable information to assess the efficacy of the treatment.

In this study, I propose to assess the treatment effect of surgery, radiation therapy and chemotherapy on lung cancer by comparing patients’ survival time and hazardous rate, adjusting for the type of the lung cancer.
Aims

1. Produce Kaplan-Meier estimates for descriptive statistics (such as the mean and median survival time of lung cancer patients in each group), plot survival curves.
2. Perform Log-rank test to compare the survival curves.
3. Use the Cox proportional hazards model to compare the hazard rates among lung cancer patients treated by surgery, radiation therapy or chemotherapy, adjusting for the type of the lung cancer.

Collaborators

Dr. Fares Qeadan